Association Maladie de Rendu-Osler   Report issue

Foundation Phase 3
Founded: Fouesnant France (1992)

Organization Overview

First Clinical Trial
2019
NCT04113187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

AMRO-HHT-France - Association Maladie de Rendu-Osler

Active Ingredients

Drugs in Phase 3 Trials (1)

propranolol (inderal) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epistaxis (Phase 3)

Telangiectasia, Hereditary Hemorrhagic (Phase 3)

Telangiectasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1